Effect of Treatment With Metformin in Type 2 Diabetes Patients on Alternative Genes Splicing Whose Maturation Depends on the Protein HuR, Including Gene Encoding Insulin Receptor
Overview
- Phase
- Not Applicable
- Intervention
- Metformin
- Conditions
- Type 2 Diabetes
- Sponsor
- Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
- Enrollment
- 25
- Locations
- 1
- Primary Endpoint
- Comparison of expression of isoforms A and B of the insulin receptor using quantitative RT PCR
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
Main objective : Show that treatment with metformin in patients with type 2 diabetes has an effect on alternative splicing of the insulin receptor.
Secondary objective : demonstrate that the effect on the ratio A/isoform B isoform with discontinuation of treatment with metformin can be réversé by the resumption of metformin treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Type 2 Diabetic patients usually treated with metformin (≥ 1400 mg/day), associated or not to other oral anti-diabetic treatment or. injection treatment
- •Patients major.
- •Patients with a social security number
- •Patients having signed a consent to participate in the study
Exclusion Criteria
- •Intolerance metformin
- •Patients with type
- •Patients on pioglitazone or rosiglitazone
- •Renal failure by an anomaly of the creatinine clearance (\< 60 mL/min).
- •Patients pregnant or likely to be.
Arms & Interventions
Arm1
During their visit of consultation on the follow-up to the type 2 diabetes, les patients will be selected on the basis of active metformin treatment at a dose greater than or equal to 1400 mg/day. Patients will have to achieve a 10 ml blood sample. The blood will be processed by Ficoll gradient centrifugation to remove the red cells and isolate circulating leukocytes: this stage will be conducted in the CERITD. Analysis on circulating leukocytes and in particular the quantification of expressions of isoforms A and B of the INSR1 by quantitative RT - PCR gene will be conducted in the laboratory of the Professor Marc Peschanski (unit INSERM 861 I - STEM of Evry). After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31.
Intervention: Metformin
Outcomes
Primary Outcomes
Comparison of expression of isoforms A and B of the insulin receptor using quantitative RT PCR
Time Frame: inclusion (baseline), 30th days and 60th days
comparison of the A isoform (without inclusion of exon 11) and B isoform (with inclusion of exon 11) ratio of the receptor in insulin, during the first period (without metformin) and the second period (with metformin)